ArticleCancer science2014
NRD1, which encodes nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and MMP3 expression.
Article in Cancer science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Nardilysin: classical functions and new horizons in autoimmunity.Frontiers in immunology · 2026Review
- Elevated Serum Nardilysin Is Inversely Associated with Cardiovascular Disease in Kidney Transplant Recipients.Kidney & blood pressure research · 2026Article
- Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.Journal of clinical medicine · 2022Article
- Mitochondrial calcium uniporter promotes cell proliferation and migration in esophageal cancer.Oncology letters · 2021Article
- Preeclampsia-Associated lncRNAMolecular therapy. Nucleic acids · 2020Article
- The prognostic value of a seven-lncRNA signature in patients with esophageal squamous cell carcinoma: a lncRNA expression analysis.Journal of translational medicine · 2020Article
- Integrated analysis of genomic and transcriptomic profiles identified a prognostic immunohistochemistry panel for esophageal squamous cell cancer.Cancer medicine · 2020Article
- Nardilysin controls intestinal tumorigenesis through HDAC1/p53-dependent transcriptional regulation.JCI insight · 2018Article
- Matrix metalloproteinase-1 facilitates MSC migration via cleavage of IGF-2/IGFBP2 complex.FEBS open bio · 2018Article
- Genome-wide profiling of nardilysin target genes reveals its role in epigenetic regulation and cell cycle progression.Scientific reports · 2017Article
- Nardilysin promotes hepatocellular carcinoma through activation of signal transducer and activator of transcription 3.Cancer science · 2017Article
- Diagnostic marker signature for esophageal cancer from transcriptome analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Ultrastructural localization and distribution of Nardilysin in mammalian male germ cells.Basic and clinical andrology · 2016Article
- Androgen receptor promotes esophageal cancer cell migration and proliferation via matrix metalloproteinase 2.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Proteomic Study to Survey the CIGB-552 Antitumor Effect.BioMed research international · 2015Article
- Capn4 is a marker of poor clinical outcomes and promotes nasopharyngeal carcinoma metastasis via nuclear factor-κB-induced matrix metalloproteinase 2 expression.Cancer science · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies worldwide. In the present study, to identify novel prognostic markers or therapeutic targets for ESCC, we reviewed a list of genes with upregulated expression in ESCC compared with normal esophagus, as identified by our serial analysis of gene expression (SAGE) analysis. We focused on the NRD1 gene, which encodes the nardilysin protein. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in 34 ESCC tissue samples revealed that mRNA expression of NRD1 was upregulated in 56% of ESCC tissue samples. Immunohistochemical analysis of nardilysin in 109 ESCC tissue samples demonstrated that 43 (39%) ESCC cases were positive for nardilysin. Nardilysin-positive ESCC cases were more advanced in terms of T classification (P = 0.0007), N classification (P = 0.0164), and tumor stage (P < 0.0001) than nardilysin-negative ESCC cases. Furthermore, nardilysin expression was significantly associated with poorer prognosis (P = 0.0258). Univariate and multivariate analyses revealed that nardilysin expression is an independent prognostic classifier of patients with ESCC. The invasiveness of NRD1-knockdown TE1 and TE5 esophageal cancer cell lines was less than that of the negative control siRNA-transfected cell lines. Expression of MMP2 and MMP3 mRNA was significantly lower in NRD1-knockdown TE5 cells than in negative control siRNA-transfected cells. These results suggest that nardilysin is involved in tumor progression, and is an independent prognostic classifier in patients with ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.